The Opsonic Capacity of Monoclonal Antibodies Against Escherichia Coli 0111 and Its Rough Mutant E. Coli J5

Complement activating and opsonic capacity of MAb
  • J. Verhoef
  • R. W. Vreede
  • A. S. Bouter
Conference paper
Part of the NATO ASI Series book series (volume 24)


Six monoclonal antibodies raised against Escherichia coli 0111 and against its rough mutant (chemotype Rc) were studied. One IgG2A against E. coli J5, one IgM anti-J5 and one IgG2a anti-0111 monoclonal antibody did not bind to lipopolysaccharides of the homologous strain, but cross-reacted with heterologous gram-negative rods in an enzyme-linked immunosorbent assay. These three monoclonal antibodies activated complement when incubated with homologous or heterologous strains, but were opsonic neither in the presence nor in the absence of complement. The other three monoclonal antibodies were directed against lipopolysaccharide of the homologous strain, but showed no cross-reactivity. However, these antibodies cross-reacted when bacteria were exposed to low concentrations of antibiotics (monobactams). The IgG3 and one IgM anti-J5 monoclonal antibodies activated complement and were opsonic only in the presence of complement. The IgM anti-0111 monoclonal antibody activated complement and was opsonic both in the presence and absence of complement.


Ascites Fluid Normal Human Serum Opsonic Activity Homologous Strain Heterologous Strain 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Luderitz O, Staub AM, Westphal O (1966) Immunochemistry of O and R antigens of Salmonella and related Enterobacteriaceae. Bacteriological Reviews 30: 192–255.Google Scholar
  2. 2.
    Braude AI, Douglas H (1972) Passive immunization against the local Schwartzman reaction. J Immunol 108: 505–512.PubMedGoogle Scholar
  3. 3.
    Davis CE, Ziegler EJ, Arnold KF (1978) Neutralization of meningococ- cal endotoxin by antibody to core glycolipid. J Exp Med 147: 1007–1017.PubMedCrossRefGoogle Scholar
  4. 4.
    Johns M, Skehill A, McCabe WR (1983) Immunization with rough mutants of Salmonella minnesota. IV. Protection by antisera to 0 and rough antigens against endotoxin. J Infect Dis 147: 57–67.PubMedCrossRefGoogle Scholar
  5. 5.
    Marks MI, Ziegler EJ, Douglas H, Corbeil LB, Braude AI (1982) Induc- tion of immunity against lethal Haemouhilus influenzae type b infection by Escherichia coli core lipopolysaccharide. J Clin Invest 69: 742–749.PubMedCrossRefGoogle Scholar
  6. 6.
    McCabe WR (1972) Immunization with R mutants of Salmonella minnesota. I. Protection against challenge with heterologous gram-negative bacilli. J Immunol 108: 601–610.PubMedGoogle Scholar
  7. 7.
    Young LS, Stevens P, Ingram J (1975) Functional role of antibody against “core” glycolipid of Enterobacteriaceae. J Clin Invest 56: 850–861.PubMedCrossRefGoogle Scholar
  8. 8.
    Ziegler EJ, Douglas H, Sherman JE, Davis CE, Braude AI (1973) Treat- ment of E. coli and Klebsiella bacteremia in agranulocytic animals with antiserum to a UDP-gal epimerase-deficient mutant. J Immunol 111: 433–438.Google Scholar
  9. 9.
    Ziegler EJ, McCutchan JA, Fierer J, Glauser MP, Sadoff JC, Douglas BS, Braude AI (1982) Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. New Eng J Med 307: 1225–1230.PubMedCrossRefGoogle Scholar
  10. 10.
    Wolff SM (1982) The treatment of gram-negative bacteremia and shock. Editorial. New Eng J Med 307: 1267–1268.CrossRefGoogle Scholar
  11. 11.
    Kirkland TN, Ziegler EJ (1984) An immunoprotective monoclonal anti- body to lipopolysaccharide. J Immunol 132: 2590–2592.PubMedGoogle Scholar
  12. 12.
    Nelles MJ, Niswander CA (1984) Mouse monoclonal antibodies reactive with J5 lipopolysaccharide exhibit extensive serological cross-reactivity with a variety of gram-negative bacteria. Infect Immunity 46: 677–681.Google Scholar
  13. 13.
    Vreede RW, Leuvenink J, Bouter AS, Brouwer EC, Marcelis JH, Verhoef J (1986) Complement activating and opsonic capacity of monoclonal antibodies raised against Escherichia coli 0111 and its rough mutant J5. Eur J Clin Microbiol 5: 141–147.PubMedCrossRefGoogle Scholar
  14. 14.
    Ivanoff B, André C, Fontanges R, Jourdan G (1982) Secondary immune response to oral and nasal rough mutant strains of Salmonella tvphimurium. Annales d’Immunologie (L’Institut Pasteur) 133 D: 61–70.Google Scholar
  15. 15.
    Shulman M (1978) A better cell line for making hybridomas secreting specific antibodies. Nature (London) 276: 269–270.CrossRefGoogle Scholar
  16. 16.
    Kohler G, Milstein C (1975) Continuous culture of fused cells se- creting antibody of predefined specificity. Nature (London) 256: 495–497.CrossRefGoogle Scholar
  17. Fazekas de St. Groth S, Scheidegger D (1980) Production of monoclo- nal antibodies: strategy and tactics. J Immunol Methods 35:1–21.Google Scholar
  18. 18.
    Westphal 0, Jann K (1965) Bacterial lipopolysaccharides. Methods of Carbohydrate Research 5: 83–91.Google Scholar
  19. 19.
    Galanos C, Luderitz 0, Westphal 0 (1969) A new method for the extraction of R lipopolysaccharides. Eur J Biochem 9: 245–249.PubMedCrossRefGoogle Scholar
  20. 20.
    Bos ES, van der Doelen AA, van Rooy N, Schuurs AHWM (1981) 3,3’, 5,5’-Tetramethylbenzidine as a ames test negative chromogen for horse-radish-peroxidase in enzyme-immunoassay. J Immunoassay 2: 187–204.Google Scholar
  21. 21.
    Klerx JPAM, Beukelman CJ, van Dijk H, Willers JMN (1983) Microassay for colorimetric estimation of complement activity in guinea pig, human and mouse serum. J Immunol Methods 63: 215–220.PubMedCrossRefGoogle Scholar
  22. 22.
    Boyum A (1968) Isolation of mononuclear cells and granulocytes from human blood. Scandinavian J Clin Invest 97: S77–89.Google Scholar
  23. 23.
    Verbrugh HA, Peters R, Peterson PK, Verhoef J (1978) Phagocytosis and killing of staphylococci by human polymorphonuclear and mononuclear leukocytes. J Clin Path 31: 539–545.PubMedCrossRefGoogle Scholar
  24. 24.
    Verhoef J, Peterson PK, Quie PG (1977) Kinetics of staphylococcal opsonization, attachment, ingestion and killing by human polymorphonuclear leukocytes: a quantitative assay using 3H-thymidine labeled bacteria. J Immunol Methods 14: 303–311.PubMedCrossRefGoogle Scholar
  25. 25.
    Rosenberg-Arska M, Salters MEC, van Strijp JAG, Geuze JJ, Verhoef J (1985) Electron microscopic study of phagocytosis of Escherichia coli by human polymorphonuclear leukocytes. Infect Immun 50: 852–859.Google Scholar
  26. 26.
    Overbeek BP, Schellekens JFP, Lippe W, Dekker HAT, Verhoef J (1987) Carumonam enhances reactivity of E. coli with mono-and polyclonal antisera to rough mutant E. coli J5. J Clin Microbiol 25: 1009–1013.Google Scholar
  27. 27.
    Vreede RW, Marcelis JH, Verhoef J (1986) Antibodies raised against rough mutants of E. coli and Salmonella strains are opsonic only in the presence of complement. Infect Immun 52: 892–896.Google Scholar
  28. 28.
    Couderc J, Kazatchkine MD, Ventura M, Thien Duc H, Maillet F, Thobie N, Liacopoulos P (1985) Activation of the human classical complement pathway by a mouse monoclonal hybrid IgG1–2A monovalent anti-TNP antibody bound to TNP-conjugated cells. J Immunol 134: 486–491.PubMedGoogle Scholar
  29. 29.
    Betz J, Isliker H (1981) Antibody-independent interactions between Escherichia coli J5 and human complement components. J Immunol 127: 1748–1754.PubMedGoogle Scholar
  30. 30.
    Tenner AJ, Ziccardi RJ, Cooper NR (1984) Antibody-independent Cl ac- tivation by E. coli. J Immunol 133: 886–891.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • J. Verhoef
    • 1
  • R. W. Vreede
    • 1
  • A. S. Bouter
    • 1
  1. 1.Laboratory of MicrobiologyState University of UtrechtUtrechtThe Netherlands

Personalised recommendations